Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Nov
21
Today In Oncology
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
One Surgery Could Prevent Most Ovarian Cancers
ASTRO Experts Comment on the Results of the SUPREMO Trial
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo